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The Escherichia coli rnlAB operon encodes a toxin–antitoxin module that is
involved in protection against infection by bacteriophage T4. The full-length
RnlA–RnlB toxin–antitoxin complex as well as the toxin RnlA were purified to
homogeneity and crystallized. When the affinity tag is placed on RnlA, RnlB is
largely lost during purification and the resulting crystals exclusively comprise
RnlA. A homogeneous preparation of RnlA–RnlB containing stoichiometric
amounts of both proteins could only be obtained using a His tag placed
C-terminal to RnlB. Native mass spectrometry and SAXS indicate a 1:1
stoichiometry for this RnlA–RnlB complex. Crystals of the RnlA–RnlB
complex belonged to space group C2, with unit-cell parameters a = 243.32,
b = 133.58, c = 55.64 A˚,  = 95.11, and diffracted to 2.6 A˚ resolution. The
presence of both proteins in the crystals was confirmed and the asymmetric unit
is likely to contain a heterotetramer with RnlA2:RnlB2 stoichiometry.
1. Introduction
Bacterial toxin–antitoxin (TA) modules are small operons
encoding a toxin that interferes with vital cell processes and an
antitoxin that counteracts this toxic activity (for reviews, see
Harms et al., 2018; Unterholzner et al., 2013; Van Melderen,
2010; Yamaguchi & Inouye, 2011). Currently, six classes of
TA systems have been identified based on the nature of the
antitoxin (protein or RNA) and the mechanisms that they use
to neutralize the activities of their cognate toxins (for reviews,
see Otsuka, 2016; Page & Peti, 2016). Type II TA systems form
the largest and most studied class of TA systems, with both the
toxin and the antitoxin being proteins. While originally limited
to a small number of families, currently at least 20 distinct type
II TA families can be distinguished based on the phylogeny
and activity of their toxin (Guglielmini & Van Melderen,
2011). The antitoxins in this class directly bind and inhibit the
toxin (for reviews, see Loris & Garcia-Pino, 2014; Page & Peti,
2016).
Next to the null hypothesis that they are selfish genetic
elements, three major classes of biological functions have so
far been proposed for TA modules (Van Melderen & Saavedra
De Bast, 2009). The first is the stabilization of mobile genetic
elements and unstable sections of chromosomes. They were
initially discovered on plasmids, which they stabilize via a
mechanism of post-segregational killing (Gerdes et al., 1986).
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A second possibility that has been proposed many times is
that they function in stress response and in the formation of
persisters (for a review, see Gerdes et al., 2005). Mutants of the
Escherichia coli hipAB TA module are known to have a
persister phenotype (Moyed & Bertrand, 1983; Korch et al.,
2003), but the link between other TA modules and persistence
in E. coli is weak (Ramisetty et al., 2016; Goormaghtigh et al.,
2018). Yet certain TA modules in Salmonella have been shown
to contribute to the formation of persisters in macrophages
(Helaine et al., 2014), and the mqsRA module also regulates
persister formation in Pseudomonas putida (Sun et al., 2017).
The third major function that has been proposed for TA
modules is protection against bacteriophages. A role in
bacterial suicide upon phage infection was first suggested for
E. coli mazEF (Hazan & Engelberg-Kulka, 2004). Since then,
TA-mediated abortive phage infection has been observed for
class II, III and IV TA modules (for a review, see Dy et al.,
2014). This observation is important with regard to the
renewed interest in phage therapy following increasing
multidrug resistance in bacterial pathogens. Abortive phage
infection presents a potential obstacle to treating recalcitrant
infections using this approach (Dy et al., 2014).
The E. coli rnlAB operon, together with lsoAB from the
cryptic E. coli plasmid pOSAK1, represents a poorly studied
family of type II TA systems in which rnlA encodes an
endoribonuclease (initially called RNase LS) and rnlB trans-
lates into its cognate antitoxin RnlB, which can directly bind
and neutralize RnlA (Otsuka & Yonesaki, 2005; Otsuka et al.,
2007; Koga et al., 2011). Unlike most TA modules, the rnlAB
operon is not autoregulated. Rather, evidence has been
provided that IscR, an Fe–S cluster protein, acts as a repressor
of the rnlAB operon (Otsuka et al., 2010). IscR is a tran-
scription factor that controls the expression of genes that are
necessary for Fe–S cluster biogenesis, and the biological link
to rnlAB remains unclear. 32, which controls heat-shock
response, has also been suggested to control rnlA expression,
but loose ends also remain here (Nonaka et al., 2006).
Like the related lsoAB, the rnlAB module acts as an
abortive infection system in E. coli against a T4 dmd mutant
phage (Otsuka & Yonesaki, 2012). Following infection by a T4
dmd mutant, RnlB is rapidly degraded, causing the activation
of RnlA. The endoribonucleotidic activity of RnlA leads to
the rapid degradation of late T4 mRNAs, which results in the
arrest of T4 phage propagation. However, wild-type T4 phage
can normally infect E. coli cells thanks to its own phage
antitoxin, Dmd, that binds and inhibits RnlA as well as its
homologue LsoA. This promiscuous phage antitoxin consti-
tutes a powerful counterpart to the toxin defences of the host,
successfully guaranteeing the propagation of the infection.
Hence, it is not surprising that almost all enterobacteria
phages contain Dmd homologues. Wei et al. (2016) reported
a sequence alignment including Dmd sequences from 22
Enterobacteria phages, three Yersinia phages and two Shigella
phages, which illustrates the distribution of this gene across
phage classes and strongly suggests the involvement of RnlA
as well as LsoA in defence mechanisms against various
bacteriophage infections.
In order to understand RnlA-mediated protection against
T4 phages at the molecular level, structures of the individual
proteins (RnlA, RnlB and Dmd) and their complexes are
required. Currently, structures of the isolated RnlA protein
and of isolated Dmd are available (Wei et al., 2013, 2016), as
well as that of an LsoA–Dmd complex (Wan et al., 2016).
Previous attempts to obtain a structure of the RnlA–RnlB
complex failed because RnlB is apparently highly unstable
and degrades prior to and/or during purification, leading to a
preparation that essentially contains only RnlA (Wei et al.,
2016). Here, we present the production, characterization and
crystallization of a stable stoichiometric RnlA–RnlB toxin–
antitoxin complex.
2. Materials and methods
2.1. Cloning, protein expression and purification
The coding region for the rnlA-rnlB operon (UniProtKB
accession Nos. NP_417119.1 and NP_417120.2, respectively)
was amplified from the E. coli K12 chromosome and intro-
duced into a pET-28a vector using NdeI and HindIII restric-
tion sites and the primers 50-CACCCATATGACAATCAGG
AGTTACAAAAA-30 (forward) and 50-GATCAAGCTTTCA
AAAATCCATTGACAGGA-30 (reverse). This cloning places
a His tag followed by a thrombin-cleavage site (MGSSHHH
HHHSSGLVPRGSH) at the N-terminus of RnlA. This
construct is referred to as His-RnlA–RnlB in Table 1. The
corresponding proteins will be referred to as His-RnlA and
RnlB.
The rnlA-rnlB bicistronic gene was again amplified from the
previous expression plasmid pET-28a-rnlA-rnlB using the
primers 50-GACTAGCATATGACAATCAGGAGTTACAA
AAACTTA-30 (forward) and 50-GACGAAGCGGCCGCAA
AATCCATTGACAGGACTTGG-30 (reverse), which insert
restriction sites for NdeI and NotI, and cloned into a pET-21b
vector. This construct (referred to as RnlA–RnlB-His in
Table 1) places a noncleavable 6His tag at the C-terminus of
RnlB (AAALEHHHHHH). The corresponding proteins will
be referred to as RnlA and RnlB-His. All constructs were
checked by DNA sequencing using specific vector primers
after transformation into the expression strains.
The expression plasmids were transformed into E. coli
BL21 (DE3) competent cells (Studier et al., 1990) using the
CaCl2 method (Hanahan et al., 1991). Transformed colonies
were selected on LB plates containing ampicillin
(100 mg ml1) or kanamycin (50 mg ml1), according to the
vector, and 2%(w/v) glucose and grown overnight at 310 K.
A 120 ml preculture was started from one isolated colony
inoculated into LB medium supplemented with 100 mg ml1
ampicillin or 50 mg ml1 kanamycin and 0.2%(w/v) glucose
and grown overnight at 310 K with aeration. A 100-fold
dilution of the preculture was used to start 12 bottles of 1 l
LB culture containing 100 mg ml1 ampicillin or 50 mg ml1
kanamycin and 0.2%(w/v) glucose. The cells were grown at
310 K with aeration until the OD600 reached 0.6. The
temperature was then decreased to 289 K and the cultures
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were left for a further 30 min before expression of the proteins
was induced by adding 0.5 mM isopropyl -d-1-thiogalacto-
pyranoside (IPTG). The cells were harvested by centrifuga-
tion for 20 min at 6500g (5000 rev min1 in a JLA-8.1000
rotor) and 277 K after overnight incubation at 289 K with
aeration and were subsequently resuspended in lysis buffer
(20 mM Tris–HCl pH 8, 500 mM NaCl, 2 mM -mercapto-
ethanol) and a protease-inhibitor cocktail (cOmplete, Sigma–
Aldrich/Merck). The cells were lysed using a continuous-flow
cell disruptor (Constant Systems) at 277 K and cell debris
was removed by centrifugation for 45 min at 41 700g
(18 000 rev min1 in a JA-20 rotor) and 277 K. The cleared
extract was loaded onto a nickel–nitrilotriacetic acid affinity
column (connected to an A¨KTAexplorer FPLC system, GE
Healthcare) pre-equilibrated in lysis buffer and washed with
the same buffer to remove nonbinding contaminants. Proteins
(which were assumed to be His-RnlA–RnlB or RnlA–RnlB-
His complexes) were eluted using a linear imidazole gradient
(0–500 mM) in 20 mM Tris–HCl pH 8, 500 mM NaCl, 2 mM
-mercaptoethanol) over 20 column volumes. The progress of
the purification was analysed by SDS–PAGE (Laemmli, 1970)
and a Western blot (Towbin et al., 1979) with a mouse antibody
recognizing the His tag (Bio-Rad, AbD Serotec). The frac-
tions containing His-tagged protein were pooled and
concentrated (Amicon UltraCel 10K) for subsequent size-
exclusion chromatography (SEC). A Superdex 200 (16/60)
column (GE Healthcare) was pre-equilibrated with
SEC buffer [20 mM Tris–HCl pH 8, 150 mM NaCl, 1 mM
tris(2-carboxyethyl)phosphine] and run at 1.0 ml min1. In the
case of the RnlA–RnlB-His complex, the Superdex 200 frac-
tions were pooled, concentrated and subsequently applied
onto a Superdex 75 (16/60) column pre-equilibrated with SEC
buffer. The fractions containing the presumed His-RnlA–
RnlB and RnlA–RnlB-His complexes were pooled, flash-
frozen and stored at 193 K.
2.2. Crystallization, X-ray data collection and processing
The protein samples in 20 mM Tris–HCl pH 8, 150 mM
NaCl, 1 mM tris(2-carboxyethyl)phosphine were concentrated
to 6–18 mg ml1 for His-RnlA–RnlB and to 22–44 mg ml1
for RnlA–RnlB-His. Crystallization conditions were initially
screened using a Mosquito HTS robot from TTP Labtech
(http://ttplabtech.com/) using 0.1 ml protein solution and 0.1 ml
reservoir solution in a sitting drop equilibrated against 100 ml
reservoir solution. Several commercially available screens
were used: Crystal Screen, Crystal Screen 2, PEGRx HT and
Index HT (Hampton Research), ProPlex, JCSG-plus and
MIDAS (Molecular Dimensions) and JBScreen Classics 1–4
(Jena Biosciences). Silver Bullets (Hampton Research) was
used as an additive screen during optimizations. Optimizations
of promising hits were performed manually using the hanging-
drop vapour-diffusion method in 48-well plates (Hampton
VDX greased) with drops consisting of 0.5 ml protein solution
and 0.5 ml reservoir solution equilibrated against 100 ml
reservoir solution.
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Table 1
Macromolecule-production information.
Construct His-RnlA–RnlB RnlA–RnlB-His
Source organism E. coli (strain K12) E. coli (strain K12)
DNA source K12 chromosome K12 chromosome
Forward primer 50-CACCCATATGACAATCAGGAGTTACAAAAA-30 50-GACTAGCATATGACAATCAGGAGTTACAAAAACTTA-30
Reverse primer 50-GATCAAGCTTTCAAAAATCCATTGACAGGA-30 50-GACGAAGCGGCCGCAAAATCCATTGACAGGACTTGG-30
Cloning vectors pET-28a pET-21b
Expression vectors pET-28a pET-21b
Expression host E. coli BL21 (DE3) E. coli BL21 (DE3)
Complete amino-acid sequences of the expressed proteins
His-thrombin-RnlA MGSSHHHHHHSSGLVPRGSHMTIRSYKNLNLVRANIETESRQFIEN
KNYSIQSIGPMPGSRAGLRVVFTRPGVNLATVDIFYNGDGSTTI
QYLTGANRSLGQELADHLFETINPAEFEQVNMVLQGFVETSVLP
VLELSADESHIEFREHSRNAHTVVWKIISTSYQDELTVSLHITT
GKLQIQGRPLSCYRVFTFNLAALLDLQGLEKVLIRQEDGKANIV
QQEVARTYLQTVMADAYPHLHVTAEKLLVSGLCVKLAAPDLPDY
CMLLYPELRTIEGVLKSKMSGLGMPVQQPAGFGTYFDKPAAHYI
LKPQFAATLRPEQINIISTAYTFFNVERHSLFHMETVVDASRMI
SDMARLMGKATRAWGIIKDLYIV
RnlB LFEITGINVSGALKAVVMATGFENPLSSVNEIETKLSALLGSETTG
EILFDLLCANGPEWNRFVTLEMKYGRIMLDTAKIIDEQDVPTHI
LSKLTFTLRNHPEYLEASVLSPDDVRQVLSMDF
RnlA MTIRSYKNLNLVRANIETESRQFIENKNYSIQSIGPMPGSRAGLRV
VFTRPGVNLATVDIFYNGDGSTTIQYLTGANRSLGQELADHLFE
TINPAEFEQVNMVLQGFVETSVLPVLELSADESHIEFREHSRNA
HTVVWKIISTSYQDELTVSLHITTGKLQIQGRPLSCYRVFTFNL
AALLDLQGLEKVLIRQEDGKANIVQQEVARTYLQTVMADAYPHL
HVTAEKLLVSGLCVKLAAPDLPDYCMLLYPELRTIEGVLKSKMS
GLGMPVQQPAGFGTYFDKPAAHYILKPQFAATLRPEQINIISTA
YTFFNVERHSLFHMETVVDASRMISDMARLMGKATRAWGIIKDL
YIV
RnlB-His LFEITGINVSGALKAVVMATGFENPLSSVNEIETKLSALLGSETTG
EILFDLLCANGPEWNRFVTLEMKYGRIMLDTAKIIDEQDVPTHI
LSKLTFTLRNHPEYLEASVLSPDDVRQVLSMDFAAALEHHHHHH
For data collection, crystals were flash-cooled in liquid
nitrogen after being transferred to precipitant solution
containing an additional cryoprotectant solution (20% PEG
400 for both His-RnlA–RnlB and RnlA–RnlB-His). Data for
His-RnlA–RnlB were collected on beamline ID23-1 at the
ESRF synchrotron facility, Grenoble, France, while data for
RnlA–RnlB-His were measured on beamline PROXIMA-2A
at the SOLEIL synchrotron facility, Gif-sur-Yvette, France.
All data were indexed, integrated and scaled with XDS
(Kabsch, 2010) via the XDSME interface (Legrand, 2017).
Data quality and twinning were analyzed with phenix.xtriage
(Liebschner et al., 2019) and POINTLESS (Evans, 2006).
Analysis of solvent contents was performed using the CCP4
program MATTHEWS_COEF (Kantardjieff & Rupp, 2003).
2.3. Mass-spectrometric analysis
2.3.1. Identification of RnlA and RnlB by LC-MS/MS mass
spectrometry. The protein solution was digested with trypsin
and analysed by liquid-chromatographic tandem mass spec-
trometry on an LTQ XL IT mass spectrometer (Thermo
Scientific, San Jose´, California, USA) equipped with a
microflow ESI source. Peptides were separated by an aceto-
nitrile gradient on a C18 column and the MS scan routine was
set to analyse the five most intense ions of each full MS scan by
MS/MS. Dynamic exclusion was enabled to assure the detec-
tion of co-eluting peptides. Peak lists were generated using
extract-msn (Thermo Scientific) within Proteome Discoverer
1.4.1. From the raw data files, MS/MS spectra were exported
with the following settings: peptide mass range 350–5000 Da,
minimal total ion intensity 500. The resulting peak lists were
searched using SequestHT against a target-decoy RnlA6His
protein database (RnlA entries comprising forward and
reversed sequences). The following parameters were used:
trypsin was selected with proteolytic cleavage only after
arginine and lysine, the number of internal cleavage sites was
set to 1, the mass tolerance for precursors and fragment ions
was 1.0 Da, considered dynamic modifications of +15.99 Da
for oxidized methionine. Peptide matches were filtered using
the q-value and posterior error probability calculated by the
Percolator algorithm ensuring an estimated false-positive rate
of below 5%. The filtered SequestHT output files for each
peptide were grouped according to the protein from which
they were derived, and their individual number of peptide
spectral matches was taken as an indicator of protein abun-
dance.
2.3.2. Native mass-spectrometric analysis. Native mass
spectrometry was performed on a Synapt G2 mass spectro-
meter (Waters, Wilmslow, England). Samples were introduced
into the gas phase at a concentration of 1.8 mM in 150 mM
ammonium acetate pH 7.8 using nano-electrospray ionization
with in-house-prepared gold-coated borosilicate glass capil-
laries. Crystals were pre-washed three times in water before
being dissolved in 150 mM ammonium acetate pH 7.8. For the
RnlA–RnlB-His sample before crystallization, the critical
voltages throughout the instrument were a sampling-cone
voltage of 25 Vand a trap-collision energy of 10 V, whereas for
the sample with the redissolved RnlA–RnlB-His crystals these
values were 120 V for the sampling-cone voltage and 5 V for
the trap-collision energy, with pressures throughout the
instrument of 5.7 and 0.0225 mbar for the source and trap-
collision cell regions, respectively, in the case of the RnlA–
RnlB-His sample before crystallization and 7 mbar and
0.0334 mbar for the source and trap-collision cell regions,
respectively, in the case of the redissolved RnlA–RnlB-His
crystals. Spectra were externally calibrated using a 10 mg ml1
solution of caesium iodide. Analyses of the acquired spectra
were performed using MassLynx v.4.1 (Waters). Native MS
spectra were smoothed (to an extent depending on the size of
the complexes) and additionally centred to calculate mole-
cular weights.
2.4. Analytical size-exclusion chromatography and
SDS–PAGE analysis of crystals
Analytical size-exclusion chromatography of His-RnlA–
RnlB and RnlA–RnlB-His was performed on a Superdex
Increase 200 column equilibrated with 20 mM Tris–HCl pH 8,
150 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine. 0.5 ml
sample injections were used at a flow rate of 0.75 ml min1.
Bio-Rad gel-filtration standards (catalogue No. 1511901) were
used to calibrate the column in the same buffer. Molecular
weights were estimated according to Whitaker (1963).
SDS–PAGE analysis of crystals was performed in 15% gels.
The crystals were prewashed three times in reservoir solution
before being dissolved in water and subsequently run on a gel.
Proteins were stained using Coomassie Blue.
2.5. Small-angle X-ray scattering (SAXS)
SAXS data for the His-RnlA–RnlB (2.5 mg ml1) and
RnlA–RnlB-His (5.9 mg ml1) complexes were collected on
beamline BM29 at the ESRF using the SEC–SAXS setup.
Samples were applied onto a Shodex 4KW column that was
run at 0.2 ml min1 in 20 mM Tris–HCl pH 8, 150 mM NaCl,
1 mM tris(2-carboxyethyl)phosphine, 5% glycerol as the
running buffer and the resulting peaks were directly measured
in the X-ray beam. The final scattering curve was obtained by
averaging the scattering curves covering a concentration range
around the peak. Guinier plots were used to estimate Rg
values and the I0 values were estimated from extrapolation of
the Guinier region to q = 0 as implemented in the ATSAS
suite (Franke et al., 2017).
3. Results and discussion
3.1. Purification and biophysical characterization of the
His-RnlA–RnlB preparation
In our initial attempts to prepare and crystallize the RnlA–
RnlB complex, we made a construct similar to that reported
previously by Wei et al. (2013). A pET-28a plasmid containing
the rnlAB operon cloned under the control of the T7
promoter, placing a His tag at the N-terminus of RnlA, was
transformed into E. coli BL21 (DE3) cells for protein
expression. The protein was purified by Ni–NTA affinity
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chromatography followed by gel filtration. A total of 14 mg
protein was obtained per litre of culture. The corresponding
His-RnlA–RnlB preparation eluted from a Superdex Increase
200 column at a volume of 14.1 ml, which corresponds to an
estimated molecular weight of 66 kDa (Fig. 1a). Considering
that our construct renders His-RnlA with a monomeric mass
of 42.3 kDa and RnlB with a mass of 13.7 kDa, this peak could
correspond to a 1:1 stoichiometry of His-RnlA:RnlB.
However, Coomassie Blue-stained SDS–PAGE gels of these
fractions only showed a band corresponding to His-RnlA
(Fig. 1b), as also confirmed by an anti-His-tag Western blot
analysis.
The tryptic digest of the presumed His-RnlA–RnlB
complex was analysed by LC tandem mass spectrometry in
order to identify the components of the sample. A search of
the resulting peak list against the recombinant His-RnlA
sequence showed 87% coverage, including both the
N-terminus and the C-terminus of the protein, indicating that
no degradation was taking place. However, a search of the
peak list against a target-decoy E. coli protein database
showed the presence of only six unique RnlB peptides, which
relates to the low search score observed for RnlB arising from
its low relative abundance in the sample and possible degra-
dation. It is worth mentioning that BL21 (DE3), the E. coli
strain used for the expression of this construct, does not
contain the rnlAB operon. Therefore, a low number of iden-
tified peptides correspond to recombinant RnlB protein.
SAXS data for the His-RnlA–RnlB sample (2.47 mg ml1)
were collected on beamline BM29 at the ESRF. The scattering
curve for this sample is rather noisy for q values larger than
0.16 A˚1 (Fig. 2a), but the Guinier plot shows a linear beha-
viour, rendering a radius of gyration (Rg) of 34.8 A˚ (Fig. 2b).
The theoretical Rg for the crystallographic dimer in the
published His-RnlA structure (PDB entry 4i8o; Wei et al.,
2013) is 29.5 A˚, while the theoretical Rg for the PDBePISA
(https://www.ebi.ac.uk/pdbe/pisa/) biological assembly of PDB
entry 4i8o shows a value of 34.6 A˚, which is practically the
same as our Guinier Rg for His-RnlA–RnlB. This observation
strongly suggests the presence of the biological assembly of
the RnlA dimer in solution and the absence of RnlB. Addi-
tionally, the molecular weight estimated from extrapolation to
I0 is 75 kDa, which points to the presence of a His-RnlA dimer
rather than an equimolar complex between His-RnlA and
RnlB. The 2 values for the fitting of the experimental scat-
tering curve to the theoretical SAXS curves obtained from the
published structure of the His-RnlA dimer (PDB entry 4i8o;
Wei et al., 2013), for the crystallographic dimer as deposited
and for the biological assembly involving dimerization via the
C-terminal domain as generated via crystal symmetry, are 3.3
and 1.46, respectively (Fig. 2a). This again shows that our
preparation consists of pure His-RnlA dimer lacking RnlB.
3.2. Purification and biophysical characterization of the
RnlA–RnlB-His preparation
In our efforts to co-purify RnlA in complex with its anti-
toxin, the His tag was transferred to the C-terminus of RnlB.
The newly His-tagged rnlAB operon was cloned into a pET-
21b vector for expression in E. coli BL21 (DE3) cells. The
protein was purified to homogeneity by Ni–NTA affinity
chromatography followed by two consecutive gel filtrations.
The RnlA–RnlB-His-containing fractions that eluted from the
Ni–NTA column were applied onto a Superdex 200 size-
exclusion chromatography column. SDS–PAGE analysis of
these fractions showed the presence of a 20 kDa contaminant
that elutes together with the RnlA–RnlB-His complex.
Therefore, the Superdex 200 fractions were concentrated and
applied onto a Superdex 75 column for separation of this
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Figure 1
(a) Analytical size-exclusion chromatography profiles of His-RnlA–RnlB
(red) and RnlA–RnlB-His (black) samples on a Superdex 200 Increase
column. The elution volumes of the molecular-weight standards are
plotted as black squares (bovine -globulin, 158 000 Da; chicken
ovalbumin, 44 000 Da; horse myoglobin, 17 000 Da; vitamin B12,
1350 Da). The red square and the black star represent the elution
positions of the His-RnlA–RnlB and RnlA–RnlB-His peaks, respectively.
(b, c, d) 15% SDS–PAGE gels of purified fractions for His-RnlA–RnlB
(b), RnlA–RnlB-His (c) and the redissolved crystals of RnlA–RnlB-His
(d). Arrowheads mark the positions of the RnlA and RnlB-His proteins
on the gels. In (b) the only visible band corresponds to His-RnlA, and
RnlB is not detected by Coomassie staining. RnlA and RnlB-His bands
are both visible on the gels in (c) and (d) (the presence of RnlB-His was
further confirmed by an anti-His Western blot). The Thermo Fisher
Prestained Protein Ladder 10 to 180 kDa is shown as a reference in
lane M.
contaminant. 1 mg pure RnlA–RnlB-His complex was finally
obtained per litre of culture. This RnlA–RnlB-His preparation
eluted from a Superdex Increase 200 column at a volume of
13.5 ml, corresponding to an estimated molecular weight of
97 kDa (Fig. 1a), which is a higher value than that estimated
for the His-RnlA–RnlB sample measured under the same
conditions, and could correspond to a 2:2 RnlA:RnlB-His
complex. This time, the presence of RnlB-His was confirmed
by SDS–PAGE analysis and an anti-His-tag Western blot, as
shown in Fig. 1(c).
SEC–SAXS data for the RnlA–RnlB-His preparation were
measured on the SWING beamline. Again, the RnlA–RnlB-
His preparation, concentrated to 5.9 mg ml1, was applied
onto a Shodex column coupled to a capillary for SAXS
measurements. The average of the scattering curves for the
peak range shows a good dispersion up to q values of 0.4 A˚1
(Fig. 2c). The Rg determined via the Guinier plot for this data
set has a value of 34.6 A˚ (Fig. 2d), which is very close to the
value determined for the His-RnlA–RnlB sample. However,
the shape of the scattering curves differs greatly and the fitting
of the experimental curve from the RnlA–RnlB-His
preparation to the theoretical SAXS curves for the RnlA
biological assembly and crystallographic dimers (PDB entry
4i8o) show 2 values of 55.4 and 24.2, respectively (Fig. 2c).
The molecular weight estimated from analysis of the Porod
volume showed a median value of 99.53  3.83 kDa, while
analysis of the volume of correlation yielded a median value of
115.47 kDa. These values both agree well with the theoretical
molecular weight of a 2:2 RnlA:RnlB-His complex, the value
for which is 109.8 kDa.
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Figure 2
Small-angle X-ray scattering. (a, b) Scattering curves after background subtraction (a) and Guinier plots (b) for His-RnlA–RnlB (applied at
2.47 mg ml1 onto a Shodex column). The fit to the theoretical SAXS curve for the biological RnlA dimer (red curve) rendered a 2 value of 1.46, while
the fit to the theoretical SAXS curve for the crystallographic dimer in PDB entry 4i8o (green curve) showed a 2 value of 3.3. (c, d) Scattering curves
after background subtraction (c) and Guinier plots (d) for RnlA–RnlB-His (applied at 5.9 mg ml1 onto a Shodex column). The fit to the theoretical
SAXS curves for the biological RnlA dimer (red curve) and the crystallographic dimer in PDB entry 4i8o (green curve) showed 2 values of 55.4 and
24.2, respectively.
In order to further assess the stoichiometry of the complex
in solution, the RnlA–RnlB-His sample in ammonium acetate
buffer was analysed by native mass spectrometry. The spec-
trum recorded for this sample at a concentration of 1.8 mM
shows peaks corresponding to different charge states of
complexes with 2:2 and 2:1 RnlA:RnlB-His stoichiometries
(Fig. 3a). This result confirms the presence of both RnlA and
RnlB in a heterotetrameric complex in solution, as first
suggested by the SAXS measurements and the analytical SEC
experiments performed using this sample.
3.3. X-ray crystallography
Both protein preparations were subjected to crystallization
screening. Crystals grew from the His-RnlA–RnlB prepara-
tion after a week in condition No. 22 of Crystal Screen 2
(Table 2) supplemented with 0.2 ml of condition F11 [0.2%(w/v)
pyridoxal hydrochloride, 0.2%(w/v) 20-deoxyadenosine 50-
monophosphate, 0.2%(w/v) guanosine 50-diphosphate sodium
salt, 0.2%(w/v) nalidixic acid, 0.2%(w/v) uridine 50-diphospho-
N-acetylglucosamine sodium salt, 0.02 M HEPES sodium pH
6.8] from the Silver Bullets Bio crystallization additive screen
(Hampton Research). Crystals were also observed in condi-
tion A3 of JBScreen Classic 4 (Table 2; Fig. 4a). The crystals
obtained in these two conditions are morphologically similar
and have the same unit cell and space group (P212121; a= 64.32,
b = 100.80, c = 154.09 A˚). A full data set was collected from a
crystal grown in the first condition that diffracted to 3.0 A˚
resolution (Table 3). The unit cell and space group differ from
those reported previously for His-RnlA (Wei et al., 2013) and
the volume of the asymmetric unit is slightly smaller (249 755
versus 273 262 A˚3). Assuming the presence of only His-RnlA,
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Table 2
Crystallization.
The conditions listed in the table are those for the crystals that diffracted best.
Construct His-RnlA–RnlB RnlA–RnlB-His
Method Sitting-drop vapour diffusion Hanging-drop vapour diffusion
Plate type 96-well IntelliPlate (Hampton Research) 48-well VDX greased plate (Hampton Research)
Temperature (K) 293 293
Protein concentration (mg ml1) 6–18 22–44
Buffer composition of protein
solution
20 mM Tris–HCl pH 8, 150 mM NaCl, 1 mM tris(2-carboxy-
ethyl)phosphine
20 mM Tris–HCl pH 8, 150 mM NaCl, 1 mM tris(2-carboxy-
ethyl)phosphine
Composition of reservoir solution 0.1 M MES monohydrate pH 6.5, 12% PEG 20 000 (Crystal
Screen 2 condition No. 22); 0.1 M Tris–HCl pH 8.5, 0.1 M
potassium chloride, 3% PEG 6000 (JBScreen Classic 4
condition A3)
0.1 M bis-Tris pH 6, 15%(w/v) SOKALAN CP 5 (MIDAS
condition No. 2-36); 0.1 M Tris–HCl pH 8.5, 25%(w/v)
SOKALAN CP 5 (MIDAS condition No. 2-46)
Volume and ratio of drop 0.1 ml; 1:1 protein:buffer ratio 0.5 ml; 1:1 protein:buffer ratio
Volume of reservoir (ml) 100 100
Figure 3
Native mass-spectrometric analysis of RnlA–RnlB-His samples. Native mass spectra of (a) the RnlA–RnlB-His sample before crystallization and (b)
resolubilized crystals after diffraction. The measured and theoretical masses of the complexes are indicated. For both samples distributions of 2RnlA
and 2RnlB (red charge states) were detected, whereas in the sample before crystallization (a) the complex lacking one RnlB is also present (blue
charge states). Critical voltages and pressures used during the measurements were 120 V on the sampling cone, 5 V trap-collision energy for the sample
in (a) and 50 V trap-collision energy for the sample in (b).
Matthews analysis (Matthews, 1968) agrees with the asym-
metric unit containing a His-RnlA dimer, with a VM value of
2.96 A˚3 Da1, a solvent content of 58.44% and a probability of
0.99.
For the RnlA–RnlB-His preparation, crystals were
obtained through variation of the protein concentration (20–
40 mg ml1) and concentration of the hit condition in water
from 20 to 80% using condition No. 2-36 of the MIDAS screen
from Molecular Dimensions [0.1 M bis-Tris pH 6, 15%(w/v)
SOKALAN CP 5] and condition No. 2-46 of the same screen
[0.1 M Tris pH 8.5, 25%(w/v) SOKALAN CP 5]. These opti-
mization plates were incubated at 293 K and large plate-
shaped crystals were observed after seven days (Fig. 4b).
These crystals belonged to space group C2, with unit-cell
parameters a = 243.32, b = 133.58, c = 55.64 A˚,  = 95.11, and
diffracted to 2.6 A˚ resolution (Table 3).
SDS–PAGE analysis as well as native mass-spectrometric
analysis of washed and redissolved crystals of RnlA–RnlB-His
clearly indicated the presence of both RnlA and RnlB-His in a
2:2 stoichiometry (Figs. 1d and 3b), showing that in this case it
is indeed the complex that has been crystallized. Matthews
analysis (Kantardjieff & Rupp, 2003) suggests the presence of
both RnlA and RnlB-His in a 2:2 stoichiometry in the asym-
metric unit, with a VM of 2.23 A˚
3 Da1 and a corresponding
solvent content of 44.86%. While SDS–PAGE and mass
spectrometry show that both proteins are intact without any
signs of significant degradation (Figs. 1d and 3b), we failed to
obtain a molecular-replacement solution using the published
structure of His-RnlA (PDB entry 4i8o; Wei et al., 2013).
Furthermore, attempts to solve the structure by repeating the
molecular-replacement search using individual domains were
also not successful, and only two copies of the C-terminal
domain of His-RnlA could be placed so far in a dimeric
arrangement that does not reproduce the native dimer in PDB
entry 4i8o. This partial solution (LLG = 686), however, was
insufficient to obtain an interpretable map for the missing
RnlA domains and the RnlB structure. This indicates that
upon binding to RnlB, RnlA is likely to undergo significant
conformational changes and that structure solution will
require experimental phasing.
A question remains as to why the His-RnlA–RnlB and
RnlA–RnlB-His preparations behave so differently.
According to Wei et al. (2013), RnlB is extremely unstable and
degrades when cells are disrupted, resulting in a preparation
of pure His-RnlA. Our current results, however, indicate that
replacement of the affinity tag may influence the affinity
between the proteins. When it is placed at the C-terminus of
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Table 3
Data collection and processing.
His-RnlA–RnlB RnlA–RnlB-His
Diffraction source ID23-1, ESRF PROXIMA-2A,
SOLEIL
Wavelength (A˚) 0.97 0.98
Temperature (K) 100 100
Detector PILATUS 6M EIGER X 9M
Crystal-to-detector distance
(mm)
556.67 254.69
Rotation range per image () 0.1 0.1
Total rotation range () 360 360
Space group P212121 C2
a, b, c (A˚) 64.32, 100.80, 154.09 243.32, 133.58, 55.64
, ,  () 90, 90, 90 90, 95.11, 90
Mosaicity () 0.10 0.12
Resolution range (A˚) 47.9–2.98 (3.09–2.98) 48.78–2.63 (2.73–2.63)
Total No. of reflections 144889 (11998) 350162 (30565)
No. of unique reflections 20824 (1880) 51666 (4790)
Completeness (%) 99.01 (90.9) 99.09 (92.0)
Multiplicity 7.0 (6.4) 6.8 (6.4)
hI/(I)i 9.36 (1.13) 12.10 (1.50)
Rmerge 0.18 (1.73) 0.11 (0.82)
Rmeas 0.19 (1.89) 0.12 (0.89)
CC1/2 0.99 (0.52) 0.99 (0.79)
CC* 0.99 (0.82) 0.99 (0.94)
Overall B factor from
Wilson plot (A˚2)
80.6 70.4
Figure 4
(a) Crystals from the His-RnlA–RnlB preparation (7 mg ml1) obtained
in 0.1 M MES monohydrate pH 6.5, 12% PEG 20 000 supplemented with
0.2%(w/v) pyridoxal hydrochloride, 0.2%(w/v) 20-deoxyadenosine
50-monophosphate, 0.2%(w/v) guanosine 50-diphosphate sodium salt,
0.2%(w/v) nalidixic acid, 0.2%(w/v) uridine 50-diphospho-N-acetylglucos-
amine sodium salt, 0.02 M HEPES sodium pH 6.8. (b) Crystals of the
RnlA–RnlB-His complex (44 mg ml1) obtained in 50% condition
No. 2-46 of the MIDAS crystal screen [0.1 M Tris pH 8.5, 25%(w/v)
SOKALAN CP 5].
RnlB, a stable complex can be formed that shows a stoichio-
metric composition and that readily crystallizes. On the other
hand, a polyhistidine tag at the N-terminus of RnlA may
interfere with RnlB binding, weakening the interaction
between the proteins. Within the cell, possibly owing to excess
production of RnlB (Otsuka et al., 2010), the weaker affinity
may still be sufficient to neutralize RnlA, but once diluted, the
complex may dissociate when the His tag is placed at the
N-terminus of RnlA.
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